Advice
Following a full submission.
Zoledronic acid 5mg (Aclasta) is accepted for use within NHS Scotland for the treatment of Paget’s disease of bone in patients for whom the use of a bisphosphonate is appropriate.
Zoledronic acid infusion resulted in similar levels of pain relief but greater and more sustained reduction of serum alkaline phosphatase (a marker of bone turnover) than one course of an oral bisphosphonate.
Download detailed advice47KB (PDF)
Medicine details
- Medicine name:
- zoledronic acid 5mg/100ml solution for infusion (Aclasta)
- SMC ID:
- 317/06
- Indication:
- Paget's disease of bone
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 October 2006